Keywords: NGM Pharma, Jansse, Johnson & Johnson, Diabetes, Metablic diseases, Microbiotix, Merck & Co, MBX-700/701, Hepatitis C
NGM Biopharma in deal with Janssen for novel diabetes therapeutics; Microbiotix in-licenses drugs from Merck & Co
Article | 04 January 2013
USA-based NGM Biopharmaceuticals has signed a worldwide agreement with health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
